The goal of this clinical trial is to test MGC018 in patients with relapsed or refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). The main question it aims to answer is:
• Does the administration of MGC018 achieve a clinically meaningful response rate of 25% in patients with relapsed or refractory ES-SCLC?
Participants enrolled in the trial will receive MGC018 through an intravenous (IV) infusion, every 28 days until disease progression or unacceptable toxicity. Tumor assessment will be done every 2 cycles (28 day cycles). Blood samples will be taken for biomarker analysis before treatment, on cycle 3 day 1, and at progression. A pretreatment biopsies will be done.

开始日期2024-04-15

申办/合作机构

Georgetown University Hospital

[+1]

NCT05551117 / Active, not recruiting临床2期

A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Study CP-MGC018-03 is an open-label, two-part, Phase 2 study. Part 1 of the study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT). ARAT includes abiraterone, enzalutamide, or apalutamide. Participants may have received up to 1 prior docetaxel-containing regimen, but no other chemotherapy agents.
This part of the study will assess the efficacy and tolerability of vobramitamab duocarmazine (MGC018) in two experimental arms (2.0 mg/kg every 4 weeks [Q4W] and 2.7 mg/kg Q4W) . Approximately 100 participants will be randomized 1:1.
Part 2 of the study will enroll participants with locally advanced or metastatic squamous cell carcinoma (SCC) of the anus, melanoma, head and neck squamous cell carcinoma (HNSCC), squamous non-small cell lung carcinoma (NSCLC), and small cell lung carcinoma (SCLC). Participants must have progressive following at least 1 prior line of standard chemotherapy for advanced or metastatic disease. Participants will receive vobramitamab docarmazine at a dose of 2.7 mg/kg every 4 weeks. Up to 200 participants may be enrolled in Part 2.
In both parts, vobramitamab duocarmazine will be administered intravenously (IV) in clinic on Day 1 of each 4-week cycle. Vobramitamab duocarmazine will be administered until criteria for treatment discontinuation are met. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI), bone scans, and prostate-specific antigen (PSA) blood tests. Routine examinations and blood tests will be performed and evaluated by the study doctor.

开始日期2023-06-13

申办/合作机构

MacroGenics, Inc.

NCT05293496 / Recruiting临床1期

A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors

Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled.
Vobramitamab duocarmazine and lorigerlimab are administered separately on Day 1 of every 4-week (28-day) cycle at the assigned dose for each cohort. Participants who do not meet criteria for study drug discontinuation may receive study drugs for up to 2 years.
Tumor assessments are performed every 8 weeks (± 7 days) for the initial 6 months on study drugs, then every 12 weeks (± 21 days) until progressive disease (PD).
Participants will be followed for safety throughout the study. .

开始日期2022-04-19

申办/合作机构

MacroGenics, Inc.

100 项与 vobramitamab duocarmazine 相关的临床结果

登录后查看更多信息

100 项与 vobramitamab duocarmazine 相关的转化医学

登录后查看更多信息

100 项与 vobramitamab duocarmazine 相关的专利（医药）

登录后查看更多信息

项与 vobramitamab duocarmazine 相关的文献（医药）

2023-09-01·Journal for immunotherapy of cancer

Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma

Article

作者: Bonvini, Ezio ; Bensa, Veronica ; Giusto, Elena ; Corrias, Maria Valeria ; Cilli, Michele ; Ciampi, Eleonora ; Calarco, Enzo ; Loo, Derik ; Brignole, Chiara ; Perri, Patrizia ; Pastorino, Fabio ; Ponzoni, Mirco ; Astigiano, Simonetta

Introduction:

B7-H3 is a potential target for pediatric cancers, including neuroblastoma (NB). Vobramitamab duocarmazine (also referred to as MGC018 and herein referred to as vobra duo) is an investigational duocarmycin-based antibody-drug conjugate (ADC) directed against the B7-H3 antigen. It is composed of an anti-B7-H3 humanized IgG1/kappa monoclonal antibody chemically conjugated through a cleavable valine-citrulline linker to aduocarmycin-hydroxybenzamideazaindole (vc-seco-DUBA). Vobra duo has shown preliminary clinical activity in B7-H3-expressing tumors.

Methods:

B7-H3 expression was evaluated by flow-cytometry in a panel of human NB cell lines. Cytotoxicity was evaluated in monolayer and in multicellular tumor spheroid (MCTS) models by the water-soluble tetrazolium salt,MTS, proliferation assay and Cell Titer Glo 3D cell viability assay, respectively. Apoptotic cell death was investigated by annexin V staining. Orthotopic, pseudometastatic, and resected mouse NB models were developed to mimic disease conditions related to primary tumor growth, metastases, and circulating tumor cells with minimal residual disease, respectively.

Results:

All human NB cell lines expressed cell surface B7-H3 in a unimodal fashion. Vobra duo was cytotoxic in a dose-dependent and time-dependent manner against all cell lines (IC50 range 5.1–53.9 ng/mL) and NB MCTS (IC50 range 17.8–364 ng/mL). Vobra duo was inactive against a murine NB cell line (NX-S2) that did not express human B7-H3; however, NX-S2 cells were killed in the presence of vobra duo when co-cultured with human B7-H3-expressing cells, demonstrating bystander activity. In orthotopic and pseudometastatic mouse models, weekly intravenous treatments with 1 mg/kg vobra duo for 3 weeks delayed tumor growth compared with animals treated with an irrelevant (anti-CD20) duocarmycin-ADC. Vobra duo treatment for 4 weeks further increased survival in both orthotopic and resected NB models. Vobra duo compared favorably to TOpotecan-TEMozolomide (TOTEM), the standard-of-care therapy for NB relapsed disease, with tumor relapse delayed or arrested by two or three repeated 4-week vobra duo treatments, respectively. Further increased survival was observed in mice treated with vobra duo in combination with TOTEM. Vobra duo treatment was not associated with body weight loss, hematological toxicity, or clinical chemistry abnormalities.

Conclusion:

Vobra duo exerts relevant antitumor activity in preclinical B7-H3-expressing NB models and represents a potential candidate for clinical translation.

2021-01-01·Biochemical pharmacology2区 · 医学

B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy

2区 · 医学

Article

作者: Bei, Yuncheng ; Yang, Nanfei ; Song, Yue ; Cheng, Nan ; Zhang, Wenlong ; Zhang, Weijie ; Shen, Pingping ; Shu, Yuxin ; Xu, Lizhi ; Bai, Xuexia

B7-H3 is an immune checkpoint molecule from the B7 superfamily. It has been widely studied in tumor immune evasion in certain types of cancer. In our preliminary study, we found that B7-H3 is specifically enriched in tumor-associated macrophages (TAMs) in triple-negative breast cancer (TNBC) patients and strongly correlated with poor clinical prognosis. However, the role of B7-H3 in breast cancer remains elusive. Our current study aims to explore the potential of B7-H3 as a novel target in TNBC therapy. Here, we demonstrated that B7-H3 enriched on TAMs is tightly correlated with TNBC clinical progression. B7-H3^high TAMs exhibit great pro-metastatic and immunosuppressive functions by intriguing extracellular matrix (ECM) reconstruction and tumor angiogenesis, therefore helping tumor cell dissemination and dampening T-cell infiltration in tumor microenvironment (TME). Importantly, targeting blockade of B7-H3 by anti-B7-H3 antibody improves the tumor vasculature disorder, thereby enhancing chemotherapy and PD-1 therapy efficacy. In conclusion, our study establishes the correlation between B7-H3^high TAMs and TNBC progression for the first time. By exploring the possibility of targeting B7-H3 expressed in both tumor cells and TAMs, we suggest that B7-H3 could be a promising target in clinical TNBC treatment.

2020-11-01·Molecular cancer therapeutics2区 · 医学

Preclinical Development of MGC018, a Duocarmycin-based Antibody–drug Conjugate Targeting B7-H3 for Solid Cancer

2区 · 医学

Article

作者: Loo, Deryk ; Moore, Paul A. ; Koenig, Scott ; Huang, Ling ; Li, Ying ; Li, Pam ; Ciccarone, Valentina ; Tamura, James ; Chen, Francine Z. ; Gaynutdinov, Timur ; Sharma, Sharad ; Yee-Toy, Nicholas C. ; Chiechi, Michael ; De Costa, Anushka ; Hotaling, Tim E. ; Son, Thomas ; Hooley, Jeff ; Brown, Jennifer G. ; Gorlatov, Sergey ; Barat, Bhaswati ; Chen, Yan ; Li, Hua ; Wolff, Christina R. ; Easton, Ann ; Scribner, Juniper A. ; Bonvini, Ezio

Abstract:

B7-H3, also referred to as CD276, is a member of the B7 family of immune regulatory proteins. B7-H3 is overexpressed on many solid cancers, including prostate cancer, renal cell carcinoma, melanoma, squamous cell carcinoma of the head and neck, non–small cell lung cancer, and breast cancer. Overexpression of B7-H3 is associated with disease severity, risk of recurrence and reduced survival. In this article, we report the preclinical development of MGC018, an antibody–drug conjugate targeted against B7-H3. MGC018 is comprised of the cleavable linker-duocarmycin payload, valine-citrulline-seco duocarmycin hydroxybenzamide azaindole (vc-seco-DUBA), conjugated to an anti-B7-H3 humanized IgG1/kappa mAb through reduced interchain disulfides, with an average drug-to-antibody ratio of approximately 2.7. MGC018 exhibited cytotoxicity toward B7-H3–positive human tumor cell lines, and exhibited bystander killing of target-negative tumor cells when cocultured with B7-H3–positive tumor cells. MGC018 displayed potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma. In addition, antitumor activity was observed toward patient-derived xenograft models of breast, prostate, and head and neck cancer displaying heterogeneous expression of B7-H3. Importantly, MGC018 exhibited a favorable pharmacokinetic and safety profile in cynomolgus monkeys following repeat-dose administration. The antitumor activity observed preclinically with MGC018, together with the positive safety profile, provides evidence of a potentially favorable therapeutic index and supports the continued development of MGC018 for the treatment of solid cancers.

项与 vobramitamab duocarmazine 相关的新闻（医药）

2024-11-06

·Firstwordpharma

MacroGenics' ADC moves one step closer to the drug development graveyard

MacroGenics is pulling back even further on the reins of lead antibody-drug conjugate (ADC) vobramitamab duocarmazine (vobra duo). The biotech said in its quarterly earnings report Tuesday that development of the B7-H3-targeting ADC is officially paused until it has complete safety and efficacy data from the Phase II TAMARACK study in-hand.Whether those results will support continued work on vobra duo, formerly MGC018, remains to be seen. Patient dosing in TAMARACK, which had been enrolling individuals with metastatic castration-resistant prostate cancer (mCRPC), was paused in July shortly after the company reported five patient deaths in the trial. MacroGenics expects to have mature median progression-free survival data from TAMARACK in early 2025.Stopped studiesThe development pause affects a Phase I/II trial of the ADC in solid tumours other than mCRPC, including non–small-cell lung cancer, triple-negative breast cancer, squamous cell carcinoma of the head and neck, and melanoma.A Phase I combination study of vobra duo plus MacroGenics' experimental PD-1/CTLA-4 bispecific lorigerlimab will also remain on hold. That trial was enrolling patients with relapsed or refractory, unresectable, locally advanced or metastatic solid tumours.MacroGenics said that, in addition to the TAMARACK safety and efficacy data, its development decision on vobra duo will be based on the competitive landscape for mCRPC, clinical resource availability, and potential partnering opportunities for the ADC.

抗体药物偶联物临床1期临床2期临床终止

2024-11-04

·佰傲谷BioValley

一路崩坏的MacroGenics，CEO也要辞职了

MacroGenics局势崩坏至此？该公司联合创始人、总裁兼首席执行官Scott Koenig正在计划离职。日前，MacroGenics宣布了领导层交接，Scott Koenig计划在明年初辞去总裁兼首席执行官的职位。不过Scott Koenig将继续作为MacroGenics的顾问和股东。受到该消息的影响，MacroGenics的股价反而出现小幅度上涨。管线一款接一款失败 MacroGenics成立于2000年，是老牌抗体公司。基于其DART 、TRIDENT等技术平台，公司与赛诺菲、吉利德、Incyte、再鼎医药、天境生物等公司建立了重要的合作关系，单抗和双抗管线大多进行了授权转让。不过平台技术的安全性验证遭遇不小挑战。特别是公司重点押注的B7H3靶点，单抗，双抗产品皆这折戟于不良事件。 2019年1月，FDA叫停了CD3/B7H3双抗MGD009针对B7H3阳性实体瘤的临床I期试验，因为该临床出现了肝脏不良事件。目前公司官网已无该管线信息。 2022年7月，B7H3单抗MGA271一项治疗复发难治性头颈鳞癌的II期临床试验被MacroGenic宣布停止，原因是该临床出现了11.3%的死亡事件（62名患者中7人死亡），可能与出血事件有关。 2024年8月，B7H3 ADC药物Vobramitamab Duocarmazine（MGC-018）的II期临床TAMARACK被MacroGenic宣布停止，原因是TAMARACK试验中发生了5例患者死亡事件。不过该B7H3 ADC联合lorigerlimab（PD-1×CTLA-4 DART分子）的1/2期剂量递增研究继续患者招募，并计划于今年晚些时候进行剂量扩展研究。延伸阅读：B7H3 ADC毒性累积此外，2024年3月，艾伯维终止了与MacroGenics在ADAM9 ADC上的合作，因为临床I期数据未达预期。目前，MacroGenics重点管线有三款，分别是处于早期临床的B7H3 ADC MGC026和PD-1×CTLA-4 DART分子lorigerlimab，以及临床前的ADAM9 ADC MGC028。管线一款接着一款的失败，也就算了，毕竟管线开发失败乃是兵家常事。可难受的，还有缺钱的窘境，以及管线持续烧钱的现况。缺钱的窘境 MacroGenics共开发了三款商业化产品，分别是MARGENZA、ZYNYZ、TZIELD。 ZYNYZ和TZIELD早早的被授权出去，并为MacroGenics带来了不菲的收入，但是架不住MacroGenics花钱快啊。根据MacroGenics发布的2024年第二季度财报，公司季度净亏损5570万美元。截止第二季度，现金流只剩下1.4亿美元的MacroGenics，也有些着急了。打包出售MARGENZA MARGENZA（Margetuximab）是一款HER2单抗，于2020年获FDA批准，用于治疗转移性HER2+乳腺癌患者。值得注意的是，再鼎曾在2018年引进了Margetuximab，Margetuximab于2023年9月获得中国药监局批准，不过由于再鼎并未启动商业化运营，MacroGenics无法拿到其里程碑款项。今年早些时候，再鼎终止了与MacroGenics关于Margetuximab合作，协议已于2024年5月14日生效。 MARGENZA在MacroGenics自己商业化运营下，销售情况惨淡。根据MacroGenics发布的2024年第二季度财报，产品季度净销售额约为525万美元。如果产品不赚钱，就及时卖掉回血。 2024年10月，MacroGenics将MARGENZA打包出售给TerSera Therapeutics LLC。根据协议条款，TerSera将以4000万美元的前期付款+3500万美元的里程碑付款获得MARGENZA的全球权利。相较于MARGENZA的营收，说不上是卖了一个好价钱，但起码让MacroGenics回笼了一笔资金。指望Incyte的里程碑打款 ZYNYZ（retifanlimab）是一款PD-1单抗，于2017年授权给Incyte。ZYNYZ于2023年3月23日首次获得FDA批准，用于治疗转移性或复发局部晚期默克尔细胞癌（MCC）成人患者。根据Incyte公司财报，ZYNYZ在今年前六个月的销售额仅为100万美元。延伸阅读：FDA加速批准PD-1单抗一线治疗默克尔细胞癌 MacroGenics与Incyte于2024年7月达成协议，宣布已经实现与retifanlimab开发进度相关的1亿美元里程碑。此外，MacroGenics还有资格从Incyte获得高达 2.1亿美元的剩余开发和监管里程碑，以及高达3.3亿美元的潜在商业里程碑。以及，MacroGenics从Incyte获得该产品全球净销售额的15%至24%的分层特许权使用费。 TZIELD早就被卖了 TZIELD（teplizumab）是一款CD3单抗，于2018年授权给了Provention Bio。TZIELD于2022年11月获得FDA批准，用于预防/延缓1型糖尿病。 2023年3月，赛诺菲以约29亿美元收购了Provention Bio，获得了TZIELD。延伸阅读：1型糖尿病百年首个革命性疗法，CD3单抗终获批 MacroGenics原本还拥有TZIELD的专利权，能够获得TZIELD全球净销售额的个位数专利使用费。但是由于MacroGenics等不及这笔权益慢慢变现，直接就在2024年3月将Tzield的专利权以1亿美元的预付款出售给了药物专利权收购公司DRI Healthcare Trust。小结 MacroGenics共开发了三款商业化产品，但三款产品现在都不属于MacroGenics了。作为技术公司，不善商业操作，将管线授权出去也是一种优选择。但是MacroGenics孵化了三款商业化产品，手握专利权，按理来说，应该是躺下收钱了。参考资料： 1.https://ir.macrogenics.com/news-releases/news-release-details/macrogenics-announces-leadership-transition 2.https://ir.macrogenics.com/news-releases/news-release-details/macrogenics-provides-update-corporate-progress-second-quarter 本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处 · · · · · · · ·

财报抗体药物偶联物临床2期临床1期引进/卖出

2024-10-30

·GlobeNewswire-Health Care

MacroGenics Announces Leadership Transition

Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company’s Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process. William Heiden, Chairman of the Board of Directors said, “Scott was a co-founder of MacroGenics twenty-four years ago and the Company has achieved many milestones under his leadership – including several partnered or company-owned FDA approved monoclonal antibody therapeutics developed by the company. On behalf of the Board, I want to thank Scott for his incredible dedication to the Company’s mission of discovering and developing novel therapeutics to improve patient care.” Mr. Heiden continued, “Today, MacroGenics has several innovative antibody-based therapeutics in development for the treatment of cancer, as well as significant alliances with leading pharmaceutical and biotechnology companies to develop and commercialize novel therapeutics. The Company today has a broad portfolio of promising assets and a strong balance sheet, and the Board and Scott agreed that this is the right time to transition to our next phase of leadership. We look forward to continuing to benefit from his perspectives as an advisor and shareholder.” “I am proud of our many achievements since our founding in 2000, in which we built a fully integrated, science-focused biotechnology company and have been successful in discovering, developing, manufacturing, and commercializing novel immunotherapeutics derived from our proprietary Fc-engineered antibody, bi-specific DART molecule, and antibody drug conjugate (ADC) technologies,” said Dr. Koenig. “Since the company’s IPO in 2013, we were able to fund a significant part of the development portfolio through the achievement of over $1 billion of non-dilutive capital via partnerships. Thanks to the incredible passion and dedication of the people at MacroGenics, three novel therapeutics from our pipeline advanced to approval, including MARGENZA® and ZYNYZ® to treat patients with cancer, and TZIELD® for individuals with early-stage Type 1 diabetes, and we have advanced a rich portfolio of clinical and preclinical molecules in development. I am confident that MacroGenics is well positioned in its current mission to address the significant unmet medical needs of patients with cancer. I look forward to continuing to support the Company in its work to achieve its key strategic objectives and create value for all our stakeholders.” About MacroGenics, Inc. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and MARGENZA are trademarks or registered trademarks of MacroGenics, Inc. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of and regulatory plans for the Company’s therapeutic candidates, expected timing of the release of final safety and efficacy data, including mature median rPFS and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential,” “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate’s revenue, expenses and costs may not be as expected, risks relating to TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate’s market acceptance, competition, reimbursement and regulatory actions; future data updates, especially timing and results of mature median radiographic progression-free survival, other efficacy and safety data with respect to vobramitamab duocarmazine; our ability to provide manufacturing services to our customers; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations of expanding ongoing clinical trials; availability and timing of data from ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises; costs of litigation and the failure to successfully defend lawsuits and other claims against us; and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. ###

高管变更IPO抗体药物偶联物

100 项与 vobramitamab duocarmazine 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
去势抵抗性前列腺癌	临床3期	美国	MacroGenics, Inc.	2022-07-11
黑色素瘤	临床3期	美国	MacroGenics, Inc.	2022-07-11
非小细胞肺癌	临床3期	美国	MacroGenics, Inc.	2022-07-11
广泛期小细胞肺癌	临床2期	美国	MacroGenics, Inc.	2024-04-15
肛门肿瘤	临床2期	美国	MacroGenics, Inc.	2023-06-13
肛门肿瘤	临床2期	澳大利亚	MacroGenics, Inc.	2023-06-13
肛门肿瘤	临床2期	比利时	MacroGenics, Inc.	2023-06-13
肛门肿瘤	临床2期	法国	MacroGenics, Inc.	2023-06-13
肛门肿瘤	临床2期	意大利	MacroGenics, Inc.	2023-06-13
肛门肿瘤	临床2期	波兰	MacroGenics, Inc.	2023-06-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05551117 (TAMARACK, ESMO2024) 人工标引	临床2期	转移性去势抵抗性前列腺癌	176	Vobra duo 2.0 mg/kg	築夢鏇願壓淵顧遞願願(積遞選鹹製鏇觸觸糧鑰) = 鹽製鹹襯齋齋獵構鑰襯衊糧壓蓋壓艱餘蓋餘壓 (襯窪窪憲廠鑰糧廠築淵 ) 更多	积极	2024-09-15
				Vobra duo 2.7 mg/kg	築夢鏇願壓淵顧遞願願(積遞選鹹製鏇觸觸糧鑰) = 網選鬱艱網選壓積廠繭衊糧壓蓋壓艱餘蓋餘壓 (襯窪窪憲廠鑰糧廠築淵 ) 更多
NCT05551117 (Tamarack, GlobeNewswire) 人工标引	临床2期	转移性去势抵抗性前列腺癌	176	Vobramitamab duocarmazine (vobra duo) 2.0 mg/kg q4W	糧膚構廠鬱願積壓衊齋(築衊繭襯膚餘壓遞觸構) = 衊獵壓壓窪簾蓋窪糧鏇鑰繭衊膚鬱鏇築糧遞窪 (鑰夢夢醖餘鏇襯淵廠蓋 ) 更多	积极	2024-05-09
				Vobramitamab duocarmazine (vobra duo) 2.7 mg/kg q4W	糧膚構廠鬱願積壓衊齋(築衊繭襯膚餘壓遞觸構) = 憲齋願觸糧齋鹹襯憲獵鑰繭衊膚鬱鏇築糧遞窪 (鑰夢夢醖餘鏇襯淵廠蓋 ) 更多
NCT05551117 (TAMARACK, Corporate Publications) 人工标引	临床2期	转移性去势抵抗性前列腺癌	177	Vobra duo 2.0 mg/kg	選衊齋願範鹽構憲膚糧(醖鑰簾鹽繭鏇遞範蓋鏇) = 醖窪鬱製願積簾窪觸齋範蓋鬱蓋範壓繭衊壓憲 (築襯窪觸艱艱齋鏇築糧 ) 更多	积极	2024-04-03
				Vobra duo 2.7 mg/kg	選衊齋願範鹽構憲膚糧(醖鑰簾鹽繭鏇遞範蓋鏇) = 夢夢齋積製鑰艱淵廠積範蓋鬱蓋範壓繭衊壓憲 (築襯窪觸艱艱齋鏇築糧 ) 更多
NCT03729596 (MGC018, ESMO2021)	临床1期	HR阳性/HER2低表达实体瘤	49	MGC018 3 mg/kg IV	鬱獵餘鑰積鏇願襯構壓(壓網顧衊鑰觸糧願廠糧) = 廠醖鑰壓製簾衊襯蓋淵艱襯壓繭餘艱鹽顧衊繭 (鏇衊醖壓鹹蓋窪願鹽簾 )	-	2021-09-16
NCT03729596 (ASCO2021) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	29	MGC018	製襯網遞窪鏇廠願壓觸(廠選憲範壓壓顧築壓築) = 淵醖繭憲網窪窪遞艱壓鹽窪齋築餘襯夢醖夢糧 (餘製齋選淵餘獵齋範選 ) 更多	积极	2021-05-28